Rol de las células NK en el desarrollo de la respuesta inmune adaptativa mediada por LT CD8 contra antígenos tumorales
Despite the classical function of NK cells in the elimination of tumors, evidence for a regulatory role for NK cells has been emerging in different models. However, this role has not been fully explored in the context of a growing tumor. In this thesis work, we show that NK cells can limit spontaneo...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | |
| Formato: | Tesis doctoral acceptedVersion |
| Lenguaje: | Español |
| Publicado: |
Facultad de Farmacia y Bioquímica
2016
|
| Materias: | |
| Acceso en línea: | http://repositoriouba.sisbi.uba.ar/gsdl/cgi-bin/library.cgi?a=d&c=posgraafa&cl=CL1&d=HWA_1161 http://repositoriouba.sisbi.uba.ar/gsdl/collect/posgraafa/index/assoc/HWA_1161.dir/1161.PDF |
| Aporte de: |
| Sumario: | Despite the classical function of NK cells in the elimination of tumors, evidence for a regulatory role for NK cells has been emerging in different models. However, this role has not been fully explored in the context of a growing tumor. In this thesis work, we show that NK cells can limit spontaneous cross-priming of tumor antigen-specific CD8 T cells, leading to reduced memory responses. After challenge with MC57.SIY cells, NK cell-depleted mice exhibited a higher frequency of SIY-specific CD8 T cells, with enhanced effector functions. Depletion of NK cells resulted in a CD8 T cell population skewed towards an effector-memory T phenotype which was associated with enhanced recall responses and delayed tumor growth after a secondary tumor challenge with B16.SIY cells. Mechanistically, we found that tumor-primed NK cells displayed an up-regulated expression of the inhibitory molecule PD-L1 and, through interaction with PD-1 expressed on DC, limited DC activation, explaining their reduced ability to induce tumor-specific CD8 T cell priming. Our results suggest that NK cells can, in certain contexts, have an inhibitory effect on anti-tumor immunity, a finding with implications for immunotherapy in the clinic. |
|---|